MX2013008654A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2013008654A
MX2013008654A MX2013008654A MX2013008654A MX2013008654A MX 2013008654 A MX2013008654 A MX 2013008654A MX 2013008654 A MX2013008654 A MX 2013008654A MX 2013008654 A MX2013008654 A MX 2013008654A MX 2013008654 A MX2013008654 A MX 2013008654A
Authority
MX
Mexico
Prior art keywords
amino
pharmaceutically acceptable
acceptable salt
ovarian cancer
relates
Prior art date
Application number
MX2013008654A
Other languages
English (en)
Spanish (es)
Inventor
Kurt R Auger
Justin Bottsford-Miller
Anil K Sood
Original Assignee
Glaxosmithkline Intellectual Property Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Ltd filed Critical Glaxosmithkline Intellectual Property Ltd
Publication of MX2013008654A publication Critical patent/MX2013008654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2013008654A 2011-01-26 2012-01-26 Combinaciones. MX2013008654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436435P 2011-01-26 2011-01-26
PCT/US2012/022638 WO2012103276A1 (en) 2011-01-26 2012-01-26 Combinations

Publications (1)

Publication Number Publication Date
MX2013008654A true MX2013008654A (es) 2013-09-02

Family

ID=46581159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008654A MX2013008654A (es) 2011-01-26 2012-01-26 Combinaciones.

Country Status (13)

Country Link
US (2) US20130296356A1 (enExample)
EP (1) EP2667871A4 (enExample)
JP (1) JP2014503589A (enExample)
KR (1) KR20140011322A (enExample)
CN (1) CN103476413B (enExample)
AU (1) AU2012209100A1 (enExample)
BR (1) BR112013018565A2 (enExample)
CA (1) CA2825790A1 (enExample)
EA (1) EA201391076A1 (enExample)
IL (1) IL227377A0 (enExample)
MX (1) MX2013008654A (enExample)
SG (1) SG191926A1 (enExample)
WO (1) WO2012103276A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
EP2906215A4 (en) * 2012-10-12 2016-05-18 SUITS
AU2013334945A1 (en) * 2012-10-22 2015-04-23 Novartis Ag Combination
US20150306099A1 (en) * 2012-11-27 2015-10-29 Glaxosmithkline Llc Combination
EP4578449A4 (en) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034860B2 (en) * 2006-07-21 2011-10-11 Eastman Specialties Holdings Corporation Organosol plastisol compositions
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak

Also Published As

Publication number Publication date
US20160067248A1 (en) 2016-03-10
CN103476413B (zh) 2016-03-16
KR20140011322A (ko) 2014-01-28
BR112013018565A2 (pt) 2016-09-27
IL227377A0 (en) 2013-09-30
EA201391076A1 (ru) 2014-07-30
EP2667871A1 (en) 2013-12-04
SG191926A1 (en) 2013-08-30
US20130296356A1 (en) 2013-11-07
JP2014503589A (ja) 2014-02-13
WO2012103276A1 (en) 2012-08-02
AU2012209100A1 (en) 2013-08-01
CN103476413A (zh) 2013-12-25
CA2825790A1 (en) 2012-08-02
EP2667871A4 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
CO6341486A2 (es) Tratamiento y profilaxis de amiloidosis
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
BR112014010803A2 (pt) método de tratamento
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
NZ714963A (en) Compositions and methods for treating anemia
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
NZ598722A (en) Methods for treating psoriasis
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
MX356704B (es) Combinación.
BR112013018565A2 (pt) combinações
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
JP2014503589A5 (enExample)
EA201270526A1 (ru) Комбинация
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal